4D Molecular Therapeutics, Inc. (FDMT) Financial Analysis & Valuation | Quarter Chart
4D Molecular Therapeutics, Inc. (FDMT)
FDMTPrice: $8.61
Fair Value: 🔒
🔒score
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has t... more
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates ... more
Description
Shares
| Market Cap | $439.18M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David H. Kirn |
| IPO Date | 2020-12-11 | CAGR | 0.4% |
| Employees | 227 | Website | www.4dmoleculartherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
FDMT chart loading...
Fundamentals
Technicals
| Enterprise Value | $395.65M | P/E Ratio | -2.25 |
| Forward P/E | -2.54 | PEG Ratio | — |
| P/S Ratio | 5.15 | P/B Ratio | 0.99 |
| P/CF Ratio | -4.57 | P/FCF Ratio | -3.98 |
| EPS | $-3.75 | EPS Growth 1Y | -15.77% |
| EPS Growth 3Y | -22.53% | EPS Growth 5Y | -17.43% |
| Revenue Growth 1Y | 230194.59% | Gross Margin | -0.14% |
| Operating Margin | -1.87% | Profit Margin | -1.64% |
| ROE | -0.32% | ROA | -0.25% |
| ROCE | -0.31% | Current Ratio | 9.39 |
| Quick Ratio | 9.39 | Cash Ratio | 1.37 |
| Debt/Equity | 0.04 | Interest Coverage | — |
| Altman Z Score | 2.74 | Piotroski Score | 3 |